ISOVUE-200 Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Isovue-200, and when can generic versions of Isovue-200 launch?

Isovue-200 is a drug marketed by Bracco and is included in two NDAs.

The generic ingredient in ISOVUE-200 is iopamidol. There are eleven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the iopamidol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Isovue-200

A generic version of ISOVUE-200 was approved as iopamidol by HAINAN POLY on February 27^th, 2023.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for ISOVUE-200?
What are the global sales for ISOVUE-200?
What is Average Wholesale Price for ISOVUE-200?

Summary for ISOVUE-200

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	79
Clinical Trials:	20
Patent Applications:	3,591
Drug Prices:	Drug price information for ISOVUE-200
DailyMed Link:	ISOVUE-200 at DailyMed

Drug patent expirations by year for ISOVUE-200

Recent Clinical Trials for ISOVUE-200

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
NYU Langone Health	N/A
M.D. Anderson Cancer Center	N/A
National Cancer Institute (NCI)	N/A

See all ISOVUE-200 clinical trials

Pharmacology for ISOVUE-200

Drug Class	Radiographic Contrast Agent
Mechanism of Action	X-Ray Contrast Activity

US Patents and Regulatory Information for ISOVUE-200

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bracco	ISOVUE-200	iopamidol	INJECTABLE;INJECTION	018735-006	Jul 7, 1987	AP2	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Bracco	ISOVUE-200	iopamidol	INJECTABLE;INJECTION	020327-001	Oct 12, 1994		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for ISOVUE-200

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bracco	ISOVUE-200	iopamidol	INJECTABLE;INJECTION	020327-001	Oct 12, 1994	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for ISOVUE-200

See the table below for patents covering ISOVUE-200 around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Australia	8751675		⤷ Sign Up
Poland	96082		⤷ Sign Up
Mexico	5979		⤷ Sign Up
Romania	69615		⤷ Sign Up
Hungary	170216		⤷ Sign Up
Croatia	P931221	PROCESS FOR THE PREPARATION OF BIS-(DIHYDROXYPROPYLAMIDE) 5-HIDROXY-PROPYLAMINO-2,4,6-TRIIOD-ISOPHTALIC ACID	⤷ Sign Up
Croatia	P931219	PROCESS FOR THE PREPARATION OF BIS-(DIHYDROXYPROPYLAMIDES) 5-AMINO-2,4,6-TRIIODINE OF ISOPHTALIC ACID	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for ISOVUE-200

Recent Clinical Trials for ISOVUE-200

Pharmacology for ISOVUE-200

Make Better Decisions: Try a trial or see plans & pricing